September 17, 2014, 4:01 pm
Leonhardt Ventures Heart Failure Technology Showcase Las Vegas Sept. 16th, 2014First heart pacemaker able to recruit repairative stem cells to damaged heart tissue - THE MYOSTIM PACER First wireless energy microcurrent devices for directing stem cell therapy repair of damaged hearts to be presented SANTA MONICA, Calif., Sept. 14th, 2014 -- Leonhardt Ventures will showcase its cardiovascular and heart disease related technologies Tuesday, September 16th, 7pm to 8pm @ The Caesars Palace Hotel. Conveniently located in the same hotel as Heart Failure Society of America Annual Meeting that takes place September 14th to 17th in Las Vegas - http://www.hfsa.org/annual_meeting.asp. Please RSVP to Ms. Maddy Clemens at email@example.com
. The room for the meeting will depend on the number of participants signed up to attend. Ms. Clemens will email you back the exact room number shortly after you RSVP. Heart Failure treatment related technologies to be showcased include: MyoStim Pacers – http:/www.myostimpacers.com - world's first heart failure pacemaker designed to recruit reparative stem cells to damaged and weakened heart tissue via a homing signal + MyoStim Microcurrent devices for treating critical limb ischemia and diabetic leg and foot ulcers. Bioheart, Inc. – http://www.bioheartinc.com - Phase III leader in applying adult muscle stem cells to treat advanced heart failure since 1999. Only cell type known to grow new contractile muscle in the depths of scar tissue. BioPace – biological pacemaker made entirely of living cells. Preparing for first clinical case at Utrecht University The Netherlands. CoroStim – world's first vibrational energy emitting pacemaker add-on node designed to prevent plaque formation in high risk coronary arteries. AortaCell Stemergy - Wireless non-invasive energy device designed to recruit stem cells to weakened vessel wall tissue for repair. Wetling Microcurrent - http://www.wetlinghealth.com/ - wireless microcurrent device for multiple healing applications. BioLeonhardt – http://www.bioleonhardt.com - First implantable, programmable, refillable stem cell pump (20 ml chamber) and electrical stimulation combination device for multi-stage cell and gene therapy for treating advanced heart failure. Featuring combined utilization of MicroRNAs, nutrient time release SDF-1, hydrogel, cardiac stem cells, iPS cells and muscle progenitor stem cells. First method to utilize an implantable, programmable and re-fillable stem cell pump for multiple dosages of delivery over time. Stem Cell Micro Infusion Pump by Fluid Synchrony - www.fluidsynchrony.com - implantable, programmable and re-fillable stem cell micro infusion pump (2ml chamber) designed for controlled micro dose delivery of stem cells, selected growth factors and drugs over time to specific target organ locations. Cardiobridge – http://www.cardiobridge.com - Highest flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Data on 30 clinical patients will be presented. Procyrion Implantable Heart Pumps - www.procyrion.com - The Procyrion device consists of a small, continuous flow pump mounted within a self-expanding anchoring system. The device is advanced through a catheter in the femoral artery to the descending thoracic aorta. The self-expanding anchors deploy to fix the pump to the aortic wall. HeartScore - www.heartscore.co – Full lineup of cardiovascular diagnostic and @ home monitoring products. LVSens – Implantable heart sensor placed percutaneously by catheter. Valvublator - Catheter based devices for decalcifying, cell sodding and surface modifying heart valves to avoid need for implants + a removable percutaneously placed heart valve for select cases where the patients own valve cannot be regenerated immediately. The Leonhardt Ventures' Cal-X Stars Innovation Accelerator Scientific Advisory Board is made up of leading heart failure physicians, stem cell scientists, cardiologists and electrophysiologists - http://calxstars.com/scientific-advisory-board/. Portfolio companies are guided by a 70 person experienced board of mentors, advisors and management team members - http://calxstars.com/team-cal-x/ Leonhardt Vineyards (www.leonhardtvineyards.com) gold medal winning wines, sold exclusively through Trader Joes 415 stores nationwide, will be served. About Leonhardt Ventures: Since 1982 Leonhardt Ventures has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions. Leonhardt Venture's started the Cal-X Stars Business Accelerator in 2012 to guide forward cardiovascular and social good impact innovations over a 5 year period. Contact: Ms. Maddy Clemens, Meeting Scheduler @ email firstname.lastname@example.org
, Leonhardt Ventures, 1531 6th Street, Unit 401, Santa Monica, California, 90401 and Howard Leonhardt, President, at email@example.com
This PR distribution was issued via PRBuzz SOURCE Leonhardt Ventures RELATED LINKS http://www.leonhardtventures.com http://www.calxstars.com http://www.myostimpacers.com http://www.bioheartinc.com http://www.bioleonhardt.com http://www.wetlinghealth.com http://www.cardiobridge.com Read more news from Leonhardt Ventures. SOURCE Leonhardt Ventures #stemcells, #medtronc, #guidant, #bostonscientific, #st.judemedical, #biotronk, #sorinbiomedica, #crowdfunding, #santamonica, #sf, #LA, #HFSA, #heartfailure, #capricor, #mesoblast, #osiris, #cytoritherapeutics, #ISCO, #cardio3, #worldstemcellsummit, #WSCS
March 7, 2012, 6:47 pm
December 17, 2011, 10:00 am
SUNRISE, Fla., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Bioheart, Inc. (Nasdaq:BHRT) announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for nine new patent claims covering the use of electrical stimulation to enhance stem cell regeneration of damaged heart muscle.
The invention and its claims are deemed to be pioneering in that they harness the natural electro-chemical instructional program that teaches stem cells to become heart muscle and then apply this process to damaged heart muscle in patients suffering of heart failure. The stimulation not only attracts stem cells with a homing signal but also causes the release of beneficial proteins. The stimulation method may be applied with or without the injection of stem cells. The claims of the patent also cover pre-conditioning stem cells towards a cardiac phenotype by electrically stimulating them during culture before implantation into damaged heart muscle.
Bioheart built prototypes of devices that can run this electrical stimulation program and tested the proof of concept studies over the past several years leading up to this patent notice of allowance, working with Dr. Juan Chachques, Associate Professor Cardiac Surgery, Pompidou Hospital, Paris, France.
"This truly has the potential to be a landmark invention in the field of heart failure treatment," stated David Holmes, M.D., Chairman of Cardiology, Mayo Clinic, Rochester, Minnesota.
The inventors, Howard J. Leonhardt, Chairman, CEO and CTO of Bioheart, Inc. and Dr. Chachques, have previously partnered to receive other related patents for complementary devices and methods.
"We believe Bioheart's intellectual property estate is unmatched in the field of heart muscle repair," stated Howard Leonhardt.
"The best way to predict the future is to create it," stated Dr. Juan Chachques. "This invention could be regarded in the future as one of the most important developments ever in the fight to reduce the death rate from heart failure."
Bioheart, Inc. now holds the rights to more than 36 related patents with over 400 patent claims.
About Bioheart, Inc.:
Bioheart, Inc. (Nasdaq:BHRT) is committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's quality of life and reduce health care costs and hospitalizations. Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(r), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(r) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit www.bioheartinc.com.
MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.
Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to secure additional financing; (ii) the timely success and completion of our clinical trials; (iii) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (iv) regulatory approval of our product candidates; (v) our dependence on the success of our lead product candidate; (vi) our inability to predict the extent of our future losses or if or when we will become profitable; (vii) our ability to protect our intellectual property rights; and (viii) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2007, as amended by Amendment No. 1 on Form 10-K/A and its quarterly reports on Form 10-Q for the quarters ended March 31, 2008 and June 30, 2008.
CONTACT: Bioheart, Inc:
William Kline, Chief Financial Officer
RedChip Companies, Inc.
Bioheart Investor Relations:
(800) REDCHIP (733-2447), Ext. 118
Source: Bioheart, Inc.
Date: November 06, 2008 08:20 ET
December 17, 2011, 9:59 am
SUNRISE, Fla., March 17 /PRNewswire-FirstCall/ -- Bioheart, Inc.
(Nasdaq: BHRT) a biotechnology company that is focused on the development
of autologous (patient-derived) cell therapies and devices for the
treatment of chronic and acute heart damage, today announced that it has
been awarded U.S. Patent #: 7341062 (J. Chachques and H. Leonhardt) for a
method to repair damaged myocardium (heart tissue) by a combination of cell
transplantation and electrostimulation. The award of this patent brings to
more than 100 the number of related patents and patents pending to which
the company holds rights.
The patent covers methods for repairing damaged heart tissue by
providing electrostimulation to patient-derived myogenic cells either in
the laboratory while the cells are expanding or after the cells are
implanted into the damaged areas of the patient's heart. One potential
application for this technology that Bioheart is exploring is to adapt a
bi-ventricular pacemaker with a separate lead that could apply the
electrostimulation to the cell-transplanted regions. Electrostimulation
induces the cells to contract in an even more synchronized basis with the
surrounding tissue and increase their ability to release growth factors and
other beneficial proteins. This patent is complimentary to Bioheart's
previously granted patent for inducing angiogenesis by electrical
stimulation, based on research conducted by Dr. Shinichi Kanno and Dr.
Yasufumi Sato(1). Another application for this technology may be to combine
it with Bioheart's MyoCell(R) therapy for the recovery of heart muscle in
cardiac patients afflicted with damaged heart tissue.
"We are pleased with the awarding of this patent to Bioheart," said
William M. Pinon, president and chief executive officer of Bioheart. "We
believe that this procedure could one day be a cost-effective solution to
improve patient outcomes and enhance the quality of life for cardiac
About the Heart Failure Market
Heart failure is associated with significant morbidity, high incidence
of complications, frequent hospitalization and rising healthcare costs. In
the United States alone, an estimated 5 million individuals have a
diagnosis of "congestive heart failure," and an additional 500,000 new
cases are diagnosed annually.
Bioheart's lead product candidate, MyoCell, is an innovative clinical
cell therapy designed to populate regions of scar tissue within a patient's
heart with living muscle tissue for the purpose of improving cardiac
function in chronic heart failure patients. MyoCell uses adult stem cells
that are precursors to muscle cells, or myoblasts, which are derived from
the patient's own body. When injected into scar tissue within the heart
wall, myoblasts have shown to be capable of engrafting in the damaged
tissue and differentiating into mature muscle cells. The core technology
used in MyoCell has been the subject of human clinical trials conducted
over the last seven years and animal studies conducted over the last twenty
years. Our most recent clinical trials of MyoCell include the SEISMIC
Trial, a 40-patient Phase II clinical trial in various countries in Europe
and the MYOHEART Trial, a completed 20-patient Phase I dose escalation
trial in the United States. Final results of the MYOHEART Trial were
announced in January 2008. The FDA recently cleared us to proceed with a
multicenter Phase II/III trial for MyoCell in the United States, named the
MARVEL Trial, which will enroll up to 330 patients.
About Bioheart, Inc.
Bioheart, Inc. is a biotechnology company focused on the discovery,
development and, subject to regulatory approval, commercialization of
autologous cell therapies for the treatment of chronic and acute heart
damage. Its lead product candidate, MyoCell, is an innovative clinical cell
therapy designed to populate regions of scar tissue within a patient's
heart with autologous muscle cells, or cells from the patient's body, for
the purpose of improving cardiac function in chronic heart failure
patients. The company's pipeline includes multiple product candidates for
the treatment of heart damage, including Bioheart Acute Cell Therapy, an
autologous, adipose cell treatment for acute heart damage, and MyoCell II
with SDF-1(TM), a therapy utilizing autologous cells genetically modified
to express additional growth factors. The company holds rights to more than
100 related patents and patents pending.
(1) Circulation. 1999; 99:2682-2687
MyoCell and MyoCell II with SDF-1 are registered trademarks of
Except for historical matters contained herein, statements made in this
press release are forward-looking and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Without
limiting the generality of the foregoing, words such as "may," "will,"
"to," "plan," "expect," "believe," "anticipate," "intend," "could,"
"would," "estimate," or "continue" or the negative other variations thereof
or comparable terminology are intended to identify forward-looking
Investors and others are cautioned that a variety of factors, including
certain risks, may affect our business and cause actual results to differ
materially from those set forth in the forward-looking statements. These
risk factors include, without limitation, (i) our ability to secure
additional financing; (ii) the timely success and completion of our
clinical trials; (iii) the occurrence of any unacceptable side effects
during or after preclinical and clinical testing of our product candidates;
(iv) regulatory approval of our product candidates; (v) our dependence on
the success of our lead product candidate; (vi) our inability to predict
the extent of our future losses or if or when we will become profitable;
(vii) our ability to protect our intellectual property rights; (viii) our
inability to predict the extent of our future losses or if or when we will
become profitable; and (ix) intense competition . The company is also
subject to the risks and uncertainties described in its filings with the
Securities and Exchange Commission, including Post-Effective Amendment No.
5 to its Registration Statement on Form S-1 (Registration No. 333-140672)
filed on February 13, 2008.
Contact: William Kline Lytham Partners, LLC
Chief Financial Officer Joe Diaz
Nicholas Burke Joe Dorame
Vice President-Financial Operations Robert Blum
(954) 835-1500 (602) 889-9700
SOURCE Bioheart, Inc.